 SAN FRANCISCO, March 08, 2022 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research AACR Annual Meeting, which is being held from April 8-13, 2022 in New Orleans, LA. 